Inclusion Criteria:

          -  Relapsed or refractory acute leukemia and has exhausted, or is ineligible for,
             available therapeutic options

          -  Acute leukemia harboring histone-lysine N-methyltransferase 2A (KMT2A) or
             nucleophosmin 1 gene (NPM1) alterations

          -  Pretreatment clinical laboratory values meeting the following criteria: (a)
             Hematology: white blood cell (WBC) count less than or equal to (<=) 50 * 10^9/liter
             (L) (hydroxyurea may be used to lower WBC count at screening and during study; (b)
             Chemistry: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=2.5 *
             upper limit of normal (ULN), Corrected serum bilirubin <= 1.5 * ULN (participants with
             elevated bilirubinemia, such as Gilbert's syndrome, may enroll if conjugated bilirubin
             is within normal range) and renal function; Estimated or measured glomerular
             filtration rate greater than or equal to (>=) 50 milliliter per minute (mL/min)/1.73
             meter square (m^2)

          -  Eastern Cooperative Oncology Group (ECOG) performance status grade of 0, 1, or 2

          -  A woman of childbearing potential must have a negative highly sensitive serum
             beta-human chorionic gonadotropin at screening and within 48 hours prior to the first
             dose of study treatment

          -  A male must agree to all the following during the study and for 90 days after the last
             dose of study treatment: A male must agree to all the following during the study and
             for 90 days after the last dose of study treatment: (a) wear a condom when engaging in
             any activity that allows for passage of ejaculate to another person; (b) not to donate
             sperm or freeze for future use for the purpose of reproduction. In addition, the
             participant should be advised of the benefit for a female partner to use a highly
             effective method of contraception as condom may break or leak

        Exclusion Criteria:

          -  Acute promyelocytic leukemia according to World Health Organization (WHO) 2016
             criteria

          -  Known central nervous system (CNS) involvement

          -  Prior solid organ transplantation

          -  QTc according to Fridericia's formula (QTcF) for males >= 450 millisecond (msec) or
             for females >= 470 msec

          -  Exclusion criteria related to stem cell transplant: a. Willing and able to undergo
             allogeneic stem cell transplant (if clinically indicated); b. Received prior treatment
             with allogenic bone marrow or stem cell transplant <=3 months before the first dose of
             study treatment; c. Has evidence of graft versus host disease; d. Received donor
             lymphocyte infusion <=1 month before the first dose of study treatment; e. Requires
             immunosuppressant therapy (exception: daily doses <=10 milligrams (mg) prednisone or
             equivalent are allowed for adrenal replacement)

          -  Chemotherapy, targeted therapy, immunotherapy, or radiotherapy within 4 weeks or 5
             half-lives (whichever is shorter) before the planned first dose of study treatment